285 related articles for article (PubMed ID: 27012666)
1. Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance.
Chen KH; Yuan CT; Tseng LH; Shun CT; Yeh KH
J Hematol Oncol; 2016 Mar; 9():29. PubMed ID: 27012666
[TBL] [Abstract][Full Text] [Related]
2. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Le DT; Uram JN; Wang H; Bartlett BR; Kemberling H; Eyring AD; Skora AD; Luber BS; Azad NS; Laheru D; Biedrzycki B; Donehower RC; Zaheer A; Fisher GA; Crocenzi TS; Lee JJ; Duffy SM; Goldberg RM; de la Chapelle A; Koshiji M; Bhaijee F; Huebner T; Hruban RH; Wood LD; Cuka N; Pardoll DM; Papadopoulos N; Kinzler KW; Zhou S; Cornish TC; Taube JM; Anders RA; Eshleman JR; Vogelstein B; Diaz LA
N Engl J Med; 2015 Jun; 372(26):2509-20. PubMed ID: 26028255
[TBL] [Abstract][Full Text] [Related]
3. Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a
Gong J; Wang C; Lee PP; Chu P; Fakih M
J Natl Compr Canc Netw; 2017 Feb; 15(2):142-147. PubMed ID: 28188185
[TBL] [Abstract][Full Text] [Related]
4. Durable complete response to pembrolizumab in microsatellite stable colorectal cancer.
Gomar M; Najafi M; Aghili M; Cozzi S; Jahanbakhshi A
Daru; 2021 Dec; 29(2):501-506. PubMed ID: 34254265
[TBL] [Abstract][Full Text] [Related]
5. Microsatellite stability and mismatch repair proficiency in nasopharyngeal carcinoma may not predict programmed death-1 blockade resistance.
Liao X; Zhao L; Wu S; Zheng H; Chen H; Zhang H; Wang Z; Lin Q
Oncotarget; 2017 Dec; 8(68):113287-113293. PubMed ID: 29348907
[TBL] [Abstract][Full Text] [Related]
6. Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?
Lin AY; Lin E
J Hematol Oncol; 2015 Nov; 8():124. PubMed ID: 26542241
[TBL] [Abstract][Full Text] [Related]
7. Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China.
Huang J; Mo H; Zhang W; Chen X; Qu D; Wang X; Wu D; Wang X; Lan B; Yang B; Wang P; Zhang B; Yang Q; Jiao Y; Xu B
Cancer; 2019 Mar; 125(5):742-749. PubMed ID: 30508306
[TBL] [Abstract][Full Text] [Related]
8. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.
Zhao P; Li L; Jiang X; Li Q
J Hematol Oncol; 2019 May; 12(1):54. PubMed ID: 31151482
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Joshi SS; Maron SB; Catenacci DV
Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
[TBL] [Abstract][Full Text] [Related]
10. Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
Czink E; Kloor M; Goeppert B; Fröhling S; Uhrig S; Weber TF; Meinel J; Sutter C; Weiss KH; Schirmacher P; Doeberitz MVK; Jäger D; Springfeld C
Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28619747
[TBL] [Abstract][Full Text] [Related]
11. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden.
Gong J; Robertson MD; Kim E; Fakih M; Schrock AB; Tam KW; Burugapalli B; Monjazeb AM; Hendifar AE; Hitchins M; Klempner SJ; Cho M
Clin Colorectal Cancer; 2019 Dec; 18(4):307-309. PubMed ID: 31563511
[No Abstract] [Full Text] [Related]
13. Frequency of immunohistochemical loss of mismatch repair protein in double primary cancers of the colorectum and stomach in Japan.
Hayashi T; Arai M; Ueno M; Kinoshita H; Tada Y; Koizumi K; Miki Y; Yamaguchi T; Kato Y; Utsunomiya J; Muto T; Sugihara K
Dis Colon Rectum; 2006 Oct; 49(10 Suppl):S23-9. PubMed ID: 17106811
[TBL] [Abstract][Full Text] [Related]
14. The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma.
Almquist DR; Ahn DH; Bekaii-Saab TS
BioDrugs; 2020 Jun; 34(3):349-362. PubMed ID: 32246441
[TBL] [Abstract][Full Text] [Related]
15. PD-1 blockade in deficient mismatch repair mixed adenoneuroendocrine carcinoma of the stomach: new hope for an orphan disease.
Riccò B; Salati M; Reggiani Bonetti L; Dominici M; Luppi G
Tumori; 2020 Dec; 106(6):NP57-NP62. PubMed ID: 32878569
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of tyrosine kinase inhibitors combined with antiprogrammed cell death protein 1 antibody in tyrosine kinase inhibitor-responsive patients with microsatellite stable/proficient mismatch repair metastatic colorectal adenocarcinoma: protocol for open-label, single-arm trial.
Dong Q; Diao Y; Sun X; Zhou Y; Ran J; Zhang J
BMJ Open; 2022 Apr; 12(4):e049992. PubMed ID: 35379611
[TBL] [Abstract][Full Text] [Related]
17. Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.
Lee V; Murphy A; Le DT; Diaz LA
Oncologist; 2016 Oct; 21(10):1200-1211. PubMed ID: 27412392
[TBL] [Abstract][Full Text] [Related]
18. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Asaoka Y; Ijichi H; Koike K
N Engl J Med; 2015 Nov; 373(20):1979. PubMed ID: 26559583
[No Abstract] [Full Text] [Related]
19. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Diaz LA; Le DT
N Engl J Med; 2015 Nov; 373(20):1979. PubMed ID: 26559582
[No Abstract] [Full Text] [Related]
20. High tumor mutation burden in a patient with metastatic gastric cancer sensitive to trastuzumab: a case report.
Hu CT; Zhou YC; Zu LD; Fu GH; Li Q
Ann Palliat Med; 2021 May; 10(5):5846-5852. PubMed ID: 32921108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
